14-03-2025
UAE: 2,400 couples undergo premarital genetic screening; 92% found compatible
Around 2,400 couples have undergone premartial genetic screening so far with 92% found to be compatible, as part of the UAE's Genome Programme, it was announced on Friday.
Abu Dhabi Crown Prince Sheikh Khaled bin Mohammed bin Zayed Al Nahyan, who is also the Chairman of the Abu Dhabi Executive Council, chaired a meeting of the Emirates Genome Council, and the council approved programmes for newborn genetic screenings, expanded genetic screening for adults in the UAE Genome Programme, personalised fertility and cardiovascular genetic screening..
The Premarital Genetic Screening Programme was implemented from January 1, 2025 by the Ministry of Health and Prevention, in collaboration with the Department of Health – Abu Dhabi, Emirates Heath Services, Dubai Health Authority, and strategic partners.
To date, it has supported 2,428 couples, finding more than 92 per cent genetically compatible through comprehensive genetic screening of 570 genes linked to more than 840 genetic disorders. Couples who required additional support were provided personalised genetic counselling to assess and diagnose risk factors and offer potential solutions to support family planning decisions.
The programme aims to safeguard community members from hereditary diseases and empower couples to utilise genetic data to make informed decisions in family planning, preserving the health and wellbeing of community members and ensuring a healthier future for generations to come.
New population screening programmes
The Abu Dhabi Crown Prince endorsed new population screening programmes that expand the utilisation of genomic data and accelerate genome-driven personalised healthcare in the UAE. The programmes include newborn genetic screenings, enhanced screenings of adult participants in the Emirati Genome Programme, provision of personalised fertility programmes, and cardiovascular genetic screening.
The newborn genetic screening programme will assess genetic conditions with available treatments and early intervention options for infants, assessing 733 genes to test for more than 800 conditions.
Population disease screenings, for adults participating in the Emirati Genome Programme, aim to further identify actionable and relevant conditions for UAE nationals, by assessing 94 genes linked to more than 50 genetic conditions.
The personalised fertility programme assesses 186 genes linked to more than 130 genetic conditions, to provide personalised medicine recommendations and treatments for couples.
Cardiovascular screenings will provide genetic diagnosis and treatment, as well as early prevention, for cardiovascular related conditions through the assessment of more than 800 genes linked to more than 100 genetic conditions.
T2T Emirati Reference Genome study
Sheikh Khaled was briefed on the completion of the landmark Telomere-to-Telomere (T2T) Emirati Reference Genome study aimed at advancing precision medicine for communities in the UAE. The study, by the Department of Health – Abu Dhabi, in collaboration with Khalifa University and M42, bridges critical gaps in genomic data and provides a vital resource that enhances the ability to compare with other reference genomes, supporting the advancement of disease research, pharmacogenomics and the development of Emirati-specific targeted therapies.
Emirati Genome Programme progress
The Abu Dhabi Crown Prince was also updated on the progress of the Emirati Genome Programme, which has collected more than 700,000 genetic samples from citizens across the nation, marking significant progress towards the overall target of 1 million.
In addition, the Emirati Genome Programme has completed the collection of 100,000 samples from participants from different nationalities for a new initiative that leverages the UAE's advanced genomic capabilities. The project, in collaboration with M42, helps reduce gaps in genomic data globally by providing insights into genetic mutations affecting over 2.5 billion people across different ethnicities, with the aim to drive further collaboration on precision medicine research and solutions.
The Emirati Genome Programme is a key project under the National Genome Strategy and will support the transformation of healthcare services in the UAE by providing high-quality genetic data that enables researchers, physicians and scientists to identify the causes of genetic diseases, understand the type of genetic mutations, anticipate susceptibility to some diseases, and develop effective personalised healthcare plans.